MedImmune joined the Human Vaccines Project, a public-private partnership seeking to develop new vaccines and immunotherapies.
FDA approved Opdivo (nivolumab) to treat patients with non-squamous, advanced non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy.
ELI LILLY AND CO. announced plans to add 30,000 square feet and approximately 50 new jobs to its research and development presence at the Alexandria Center for Life Science in New York City.
FDA granted orphan drug designation to drug candidate BLU-554 for the treatment of hepatocellular carcinoma.
The American College of Gastroenterology announced the 23 winners of the first annual SCOPY Award, the Service Award for Colorectal Cancer Outreach, Prevention and Year-Round Excellence.
MANUEL HIDALGO was named director of the Leon V. & Marilyn L. Rosenberg Clinical Cancer Center and chief of the Division of Hematology-Oncology at Beth Israel Deaconess Medical Center. He will oversee all clinical cancer programs.
Stand Up To Cancer is making $7.5 million in research funding available to early-career scientists who are pursuing innovative approaches to cancer. Proposals may focus on any discipline within basic, translational, or clinical research.
The National Comprehensive Cancer Network unveiled a new initiative—NCCN Evidence Blocks—in the new versions of the NCCN Clinical Practice Guidelines in Oncology for Chronic Myelogenous Leukemia and Multiple Myeloma.
The 340B Drug Discount Program—designed to help hospitals that serve needy patients—is on the brink of a major revamp.
A federal judge has ruled against the Health Resources and Services Administration over provider access to 340B Drug Pricing Program discounts for orphan drugs.
